“European Panel on Low Density Lipoprotein (LDL) Subclasses”: A Statement on the Pathophysiology, Atherogenicity and Clinical Significance of LDL SubclassesDimitri P. Mikhailidis, Evangelos Liberopoulos, Vasilios G. Athyros et al.|Current Vascular Pharmacology|2011Cited by 197
Current practice in identifying and treating cardiovascular risk, with a focus on residual risk associated with atherogenic dyslipidaemiaRoberto Ferrari, Alberico L. Catapano, Carlos Aguíar et al.|European Heart Journal Supplements|2016Cited by 101
A review of the evidence on reducing macrovascular risk in patients with atherogenic dyslipidaemia: A report from an expert consensus meeting on the role of fenofibrate–statin combination therapyCarlos Aguíar, Roberto Ferrari, Eduardo Alegría et al.|Atherosclerosis Supplements|2015Cited by 84